May 11, 2015
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Amgen gets injunction against Novartis biosimilar drug
A U.S. appeals court has blocked the sale of Novartis AG’s Zarxio, a recently approved biosimilar form of Amgen Inc.’s cancer drug Neupogen, which is used to prevent infections in cancer patients undergoing chemotherapy.
On May 5, the U.S. Court of Appeals for the Federal Circuit in Washington granted Amgen's request to block the sale of Zarxio while Amgen's appeal of a lower-court ruling, which allowed the drug to go to market, is pending. The appeal case is scheduled to begin with oral arguments on June 3.
The U.S. Food and Drug Administration approved Zarxio in March. -by Rebecca Zumoff
Related
Biosimilars are on the way, but who benefits?
FDA: Novartis does not have to share information with Amgen over new biosimilar drug